Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies
Year: 2017
Type: article
Study design: Clinical Trial
Abstract: BACKGROUND: Pracinostat is a potent histone deacetylase inhibitor with antitumor activity in both solid tumor and acute myeloid leukemia (AML) cell lines. Pracinostat is reported to have modest clinical activity in patients with advanced solid tumors. Given the higher preclinical sensitivity of hematologic malignancies to pracinostat, the authors conducted a phase 1 study to assess the safety, maximum tolerated dose, recommended phase 2 dose, efficacy, pharmacokinetics, and pharmacodynamics of pracinostat in patients with advanced hematological malignancies. METHODS: Pracinostat was administered orally 3 times a week for 3 weeks on a 28-day cycle. Patients were assigned to 7 dose levels using a 3 + 3 dose escalation design. RESULTS: A total of 44 patients were enrolled, 25 of whom had AML and 14 of whom had myelodysplastic syndrome. The maximum tolerated dose was 120 mg and the recommended phase 2 dose was 60 mg. Two patients with AML achieved a response: 1 complete remission (CR) and 1 complete cytogenetic response. Despite a dose-dependent increase in the plasma concentration of pracinostat, a similar increase in histone acetylation was not observed. As an extension, 10 additional patients with myelodysplastic syndrome were enrolled to assess the safety and efficacy of pracinostat in combination with azacitidine. Six patients achieved a CR and 3 achieved a CR without platelet recovery with no added toxicity. CONCLUSIONS: The results of the current study demonstrate that pracinostat is safe, with modest single-agent activity in patients with hematological malignancies. Cancer 2017;123:4851-9. © 2017 American Cancer Society.
Source: Cancer
DOI: 10.1002/cncr.30949
Authors: Yasmin M. Abaza, Tapan M. Kadia, Elias J. Jabbour, Marina Y. Konopleva, Gautam Borthakur, Alessandra Ferrajoli, Zeev Estrov, William G. Wierda, Ana Alfonso, Toh Han Chong, Charles Chuah, Liang‐Piu Koh, Boon‐Cher Goh, Julie E. Chang, Daniel E. Durkes, Maria Cielo Foudray, Hagop M. Kantarjian, Xiao Qin Dong, Guillermo Garcia‐Manero
Institutions: The University of Texas MD Anderson Cancer Center, National Cancer Centre Singapore, National University of Singapore, Singapore General Hospital, National University Cancer Institute, Singapore, National University Hospital, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, MEI Pharma (United States)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: National Cancer Institute
Award: Cancer Center Support Grant
OpenAlex ID: W2745555207
